Gilead Nears $20 Billion Deal for Immunomedics, WSJ Says

(Bloomberg) -- Gilead Sciences Inc. is close to finalizing a deal to buy Immunomedics Inc. and its Trodelvy breast-cancer drug for more than $20 billion, the Wall Street Journal reported, citing un...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.